5-day/5-drug (5D/5D) is a novel high-dose regimen administered with autologous hematopoietic SCT (HSCT). It was designed to maximize cytoreduction via high dosing of synergistically interacting agents, while minimizing morbidity in patients with resistant neuroblastoma (NB) and ineligible for clinical trials due to myelosuppression from previous therapy. 5D/5D comprises carboplatin 500 mg/m 2 /day on days 1-2, irinotecan 50 mg/m 2 /day on days 1-3, temozolomide 250 mg/m 2 /day on days 1-3, etoposide 200 mg/m 2 /day on days 3-5 and cyclophosphamide 70 mg/kg/day on days 4-5. HSCT is on day 8. Sixteen patients received 21 courses. Treatment was in the outpatient clinic. Responses were noted against progressive disease (PD) that had developed while patients were off, or receiving only low-dose, chemotherapy but not against PD that emerged despite high-dose chemotherapy. Responses were also seen in patients with PD or stable disease after 131 I-metaiodobenzylguanidine therapy. Grade 3 toxicities were limited to transient elevations in liver enzymes (three courses) and hyponatremia (one course). Bacteremia occurred in 2/21 (10%) courses. Hematological recovery allowed patients to be enrolled on clinical trials. In conclusion, 5D/5D (including HSCT) spares vital organs, entails modest morbidity, shows activity against resistant NB and helps patients meet eligibility requirements for formal clinical trials.
INTRODUCTION
Standard chemotherapy for high-risk neuroblastoma (NB) includes dose-dense or dose-intensive and myeloablative regimens using alkylating agents, platinum compounds, topoisomerase-II inhibitors, and, most recently, the topoisomerase-I inhibitor topotecan. 1 Common salvage chemotherapy regimens for resistant NB combine topoisomerase-I inhibitors (topotecan, irinotecan) with alkylators (cyclophosphamide, temozolomide), [2] [3] [4] topoisomerase-II inhibitors (doxorubicin, etoposide) 5, 6 or both classes of drugs. 7 For patients with NB resistant to a wide range of agents, and ineligible for clinical trials, we have used a 5-day/5-drug (5D/5D) regimen consisting of carboplatin-irinotecan-temozolomideetoposide-cyclophosphamide, followed by autologous hematopoietic SCT (HSCT). The development of 5D/5D was based on previous Memorial Sloan-Kettering Cancer Center (MSKCC) studies that used its five components. [8] [9] [10] These agents have broad anti-NB activity, display synergistic antineoplastic effects, penetrate into the central nervous system and lack overlapping extramedullary toxicities. The 5D/5D regimen's manageable and tolerable acute toxicity allows outpatient administration, an important consideration given the issue of quality of life for heavily previous-treated patients.
HSCT is also performed in the outpatient setting. HSCT is necessary because high dosing makes this regimen strongly myelosuppressive, possibly even myeloablative, especially in patients with pre-existing poor hematological reserve due to previous therapy. HSCT results in normal blood counts, an eligibility requirement for clinical trials.
We now present a retrospective analysis of results with 5D/5D.
PATIENTS AND METHODS
5D/5D was used with the aim of halting progressive disease (PD) or reducing tumor burden before enrolling patients on formal protocolshence, 5D/5D was preceded and followed by staging. As with other MSKCC retrieval regimens, 3,9-11 toxicity of major organs had to be of grade p2 (National Cancer Institute Common Toxicity Criteria). In accord with MSKCC rules, informed written consents for treatment were obtained from guardians who were informed of each agent's toxicities, the certainty of pancytopenia with possible infection or hemorrhage and risks of unforeseen toxicities. The guardians were uniformly well-versed in toxicity issues, given the previous intensive therapy of all the patients. For this retrospective study, an institutional review board waiver was obtained for patient records.
Reasons for using 5D/5D in any given patient included two or more of the following: (1) the expectation that HSCT would reverse myelosuppression (from previous chemotherapy and/or metaiodobenzylguanidine (MIBG) therapy), which precluded eligibility for formal clinical trials; (2) the possibility that high dosing of synergistically interacting agents would overcome chemo-resistance; (3) no recent treatment with platinum compounds (and avoiding the ototoxicity of cisplatin); (4) NB resistant to topotecan; and (5) PBSCs were infused in the outpatient clinic 72 h post-5D/5D. G-CSF commenced 24 h after HSCT.
Because of anticipated myelosuppression and gastrointestinal side effects, plus concern about cumulative toxicity to major organs due to extensive previous therapy, patients were examined and had complete blood counts every 2-3 days post 5D/5D as outpatients and daily as inpatients. Additional blood work included kidney and liver function tests at least weekly.
Extent-of-disease evaluations
Disease status was assessed by computed tomography or magnetic resonance imaging, 123 I-MIBG scan, urine catecholamine levels and BM histology (aspirates and biopsies from bilateral posterior iliac crests, and aspirates±biopsies from bilateral anterior iliac crests). BM histology and radiological studies were read by MSKCC specialists outside the Department of Pediatrics who had no awareness of the treatment or patient status.
International NB Response Criteria 12 were used as modified in the Children's Oncology Group (COG) ANBL0532 protocol (ClinicalTrials.gov NCT00567567) to incorporate 123 I-MIBG findings: complete response (CR), no evidence of NB in soft tissue, bones or BM and catecholamines normal; very good partial response (PR), primary mass reduced by X90%, no evidence of distant disease in soft tissue, bones or BM, including negative I-MIBG scan improved in some but not all sites; no response, that is, stable disease (SD), o50% decrease but o25% increase in any existing lesion; and PD, new lesion or 425% increase in an existing lesion.
Responses were determined within 4 weeks from HSCT and were based on only one complete extent-of-disease evaluation because those who had SD or better proceeded immediately to formal clinical trials.
RESULTS

Patient characteristics
When treated with 5D/5D, 16 patients (10 males, 6 females) were 2.8-16.5 (median 6.9)-years old and 1.4-8.9 (median 2.7) years from diagnosis. Their sites of disease were BM by histology (n ¼ 2); osteomedullary by 123 I-MIBG scan (n ¼ 3) or 123 I-MIBG scan plus BM histology (n ¼ 5); or osteomedullary plus soft tissue (n ¼ 6). They had previously been enrolled on 2-9 (median 3) formal clinical trials (phase I and II studies). Fourteen patients had multiple previous relapses (2-8, median 4), one patient had a single previous relapse, and one patient had primary refractory disease (that is, MR to induction and salvage therapies).
All 16 patients had previously received (1) high-risk NB induction regimens (MSKCC, COG A3973, COG ANBL0532, rapid COJEC); (2) topotecan, including as part of induction (n ¼ 4), salvage (n ¼ 13), or both (n ¼ 3); and (3) salvage regimens that included irinotecan. Other previous chemotherapy included temozolomide (n ¼ 14), ifosfamide-carboplatin-etoposide (n ¼ 9) and myeloablative regimens with HSCT (n ¼ 4). Previous treatments also included targeted systemic radiotherapy with 131 I-MIBG (n ¼ 9), 131 I-labeled anti-G D2 3F8 monoclonal antibody (n ¼ 1) or both (n ¼ 2), and targeted compartmental radiotherapy with intrathecal infusions of radiolabeled monoclonal antibody (n ¼ 3). 13 Responses by subgroup Four patients were treated with 5D/5D for PD that developed while they were receiving low dose (grade 1-2 myelosuppressive) chemotherapy. Table 2 summarizes responses. Three had CR to 5D/5D. The CRs involved resolution of histological BM disease (the only site of the PD) after a single course of 5D/5D in two patients and normalization of BM histology and 123 I-MIBG scan after two sequential courses of 5D/5D in one patient (PR of BM and CR of 123 I-MIBG scan were documented after the first course). The fourth patient in this subset had SD involving BM histology and 123 I-MIBG scan. All four were subsequently enrolled on clinical trials: one remains event-free in CR at 16 þ months, one is alive at 10 þ months (PD at 6 months), and two died of disease at 21 and 25 months (PD at 6.5 and 11 months, respectively).
Four patients were treated with 5D/5D for PD that developed within 1-2 months of high-dose (grade 4 myelosuppressive) 5-day/5-drug regimen for resistant neuroblastoma BH Kushner et al salvage chemotherapy. Their responses to 5D/5D were 1 SD and 3 PD. One was subsequently enrolled on a clinical trial. All four died of PD within 12 months.
Three patients received 5D/5D as the initial treatment for PD that developed off chemotherapy. Responses were 2 MR (both reflecting responses by BM histology and 123 I-MIBG scans) and 1 SD. All three patients were subsequently enrolled on formal clinical trials but had PD at 4-9.5 months. One remains alive with disease at 25 þ months, one died of toxicity (unrelated to 5D/5D) at 13.5 months, and one died of PD at 35 months.
Six patients received 5D/5D as the planned first treatment after 131 I-MIBG therapy; five were subsequently enrolled on clinical trials. Three of the six had SD after the 131 I-MIBG therapy: their responses to 5D/5D were 1 PR (CR of BM, PR of 123 I-MIBG scan) and 2 SD; one remains progression-free on oral monotherapy at 26 þ months, and two are alive with disease at 9 þ and 17 þ months (PD at 6 and 16 months, respectively, including one patient who previously had SD when treated with 5D/5D for PD off chemotherapy). The other three patients had PD after the 131 I-MIBG therapy; their responses to 5D/5D were MR; one is alive with disease at 7 þ months (PD at 5 months) and two died of PD at 9 and 12.5 months, respectively.
Toxicity
Sixteen patients received 21 courses of 5D/5D: 11 patients received one course, four patients received two sequential courses of 5D/5D, and one patient received 5D/5D at two time points separated by other therapy. There were no unexpected side effects, given the known toxicities of each agent.
Modest acute toxicity (for example, grade 1-2 nausea/emesis) allowed outpatient treatment, replicating experience with the same chemotherapeutic agents at the same high doses used in other MSKCC salvage regimens. [9] [10] [11] No course was truncated for metabolic reasons but one patient developed transient cyclophosphamide-related grade 3 hyponatremia. Other toxicities included grade 1-2 mucositis in four courses and transient grade 3 elevations in liver enzymes in three courses. Cardiac and renal function remained intact. There was no hemorrhagic cystitis.
Infusions of PBSCs (X1.6 million CD34 þ cells/kg) were performed uneventfully in the outpatient clinic. All but one patient was eventually admitted for i.v. antibiotics for possible infection, but blood-borne bacterial infections were documented in only 2/21 (10%) courses and only four patients were hospitalized for 410 days. Hematological recovery was uncomplicated, with absolute neutrophil counts reaching 500/mL on day 8-22 (median 11) and the last platelet transfusion occurring on day 7-43 (median 15).
DISCUSSION
The 5D/5D regimen is one of a series of high-dose chemotherapy regimens devised to confront the wide range of challenging clinical situations among the many NB patients referred to MSKCC for salvage therapy. [9] [10] [11] In addition to having NB resistant to topotecan, which is widely used in induction and salvage therapy, 1,2,5-7 these patients typically developed widespread relapse while on a clinical trial and/or were ineligible for investigative studies due to clinical problems such as thrombocytopenia.
For these heavily prior-treated patients with a poor prognosis, the overarching goals of the MSKCC salvage regimens are to overcome chemo-resistance while minimizing morbidity. Alkylators (cyclophosphamide, ifosfamide, temozolomide) are administered in high doses in order to exploit the log-linear relationship between this class of agents and antitumor activity. In addition, the alkylators are combined with topoisomerase-1 (etoposide) or topoisomerase-II (topotecan, irinotecan) inhibitors for synergistic anti-NB effect. Taking into account the considerable previous cardio-and nephro-toxic therapies in these patients, agents posing limited risks to key organs are used. With quality of life a major concern, treatment is designed for outpatient administration, HSCT minimizes the duration of myelosuppression, and agents without debilitating side effects such as mucositis and ototoxicity are purposely selected. An additional consideration in the development of MSKCC salvage regimens, including 5D/5D, is the presence of central nervous system disease-hence, the inclusion of agents that cross the blood-brain barrier.
5D/5D had modest and no unforeseen non-hematological side effects. The daily administration of the chemotherapy was straightforward, applying methods and schedule derived from extensive previous experience with the same agents in other highdose (but non-myeloablative) salvage regimens for NB. [9] [10] [11] Outpatient treatment was feasible due to the manageable emetogenicity of each agent and small portable pumps for overnight home hydration. Acute problems included one episode of (asymptomatic) hyponatremia, an expected effect of high-dose cyclophosphamide; there was no hemorrhagic cystitis. Gastrointestinal symptoms, when they occurred, were of short duration or responsive to standard medications.
The pancytopenia from 5D/5D engendered no major clinical complications, infectious or otherwise. That welcome finding was, in part, attributable to the absence of veno-occlusive disease, mucositis and other non-hematological toxicities associated with many chemotherapeutic agents, including those alkylators (BU, melphalan, thiotepa) commonly used in myeloablative regimens. The 10% incidence of bacteremia with 5D/5D was comparable to, or lower than, rates with similarly myelosuppressive regimens. 14, 15 Patients with relapsed NB often have poor hematological reserve due to previous STC after myeloablative chemotherapy or recent 131 I-MIBG therapy; thrombocytopenia can limit treatment options and leave patients ineligible for clinical trials. This obstacle to further cytotoxic or investigative therapy can be overcome via the infusion of PBSCs. The necessity of using PBSCs to reconstitute blood counts raises the possibility of preceding that straightforward procedure with a course of chemotherapy to help control PD or to further reduce tumor burden; these anti-NB effects might improve chances of benefiting from subsequent enrollment on a clinical trial. Collecting abundant PBSCs during induction has been recommended 16 because PBSC availability broadens the range of salvage options if NB proves resistant to standard treatments. This point is evident in our present and previous reports on salvage chemotherapy for NB [9] [10] [11] and in experience with 131 I-MIBG therapy. 17 PBSC support has also allowed investigation of novel sub-myeloablative induction chemotherapy regimens against NB 15, 18, 19 and other solid tumors in children. 14, 20 In our series, PBSC infusions were performed in the outpatient clinic and engraftment was uncomplicated.
The hematological recovery post-HSCT, as also anti-NB effects of 5D/5D, helped patients meet eligibility requirements for formal clinical trials (Table 2 ). 5D/5D showed anti-NB activity against PD that developed while patients were off, or receiving only low-dose, chemotherapy, but was ineffective against PD that developed despite high-dose chemotherapy. Responses were also seen in patients with PD or SD post-131 I-MIBG therapy. As expected with phase I and II studies, disease regressions fell mainly into the MR category and most responses were of short duration (PD in 2-11 months). It may be unrealistic to expect a single course of chemotherapy to achieve major responses (CR or PR) of widespread disease resistant to the standard active anti-NB agents. Yet while receiving post-5D/5D therapies, two of the 16 patients in this series remain progression-free at 16 þ and 26 þ months, and three others achieved long-term survival 421 months.
We conclude that the 5D/5D regimen can achieve important goals in heavily prior-treated patients with chemo-resistant NB, namely, reducing tumor burden and helping patients meet 5-day/5-drug regimen for resistant neuroblastoma BH Kushner et al hematological and other eligibility requirements for formal clinical trials, with limited toxicity and acceptable morbidity.
